Redeye briefly comments on MedCap releasing preliminary Q4 2024 figures, significantly undershooting...
Ahead of Fiskars' Q4 report, we nudge up our Q4 estimates slightly and expect the company to reach t...
Redeye comments on the recent news regarding Integrum’s partnership with Intelerad.
Q4 report due Thursday, 13 February We cut adj. EBITA 4%/3%/3% on '24e/'25e/'26e Share is trading at...
Duell reported Q1 net sales at EUR 28.3m, just surpassing our forecast of EUR 27.
Xplora does not meet the 90% threshold, so delisting and forced buy-out plans are on hold unless fur...
Safello pre-announced key metrics for its Q4 2024 report due 21/02/2025.
Peer and competitor in Finland, HKFoods is out with a positive profit warning stating its 2024 compa...
Redeye makes a brief comment on today’s news of the CEO replacement.
Redeye provides a brief comment on Flexion Mobile’s new agreement with King, under which Flexion Mob...
Q4e: Clean paper EBIT of ~PLN 10m Paper prices down, demand muted Fair value range of SEK 40-80 Thi...
Q4e: clean EBIT of ~SEK -90m, Q1 should be better Pulp prices down, but hikes announced Fair value r...
Preliminary Q4 EBITA ~40% below FactSet consensus We expect consensus to cut '25 EBITA by ~15% and '...
Xplora Technologies AS announced a public offer on September 26, 2024, to acquire all shares in Doro...
Redeye comments on Nanologica following the annonucement of a SEK8.
Redeye comments on Ortoma’s announcement yesterday that they have submitted a supplemental 510(k) to...
Redeye comments on CLS’s recap of 2024 and outlook for 2025-2026.
Redeye comments on SciBase’s announcement of its preliminary results for the capital raise this morn...
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered into a non-bi...
Ahead of Elanders' Q4 report, we lower 2024E adjusted EBITA by 2%, while we raise 2025E-26E by 2%.
